Logo image of EPIX

ESSA Pharma Inc (EPIX) Stock Fundamental Analysis

USA - NASDAQ:EPIX - CA29668H7085 - Common Stock

0.2012 USD
0 (-1.85%)
Last: 10/8/2025, 8:00:02 PM
0.1951 USD
-0.01 (-3.03%)
After Hours: 10/8/2025, 8:00:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to EPIX. EPIX was compared to 531 industry peers in the Biotechnology industry. EPIX has a great financial health rating, but its profitability evaluates not so good. EPIX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

EPIX had negative earnings in the past year.
EPIX had a negative operating cash flow in the past year.
EPIX had negative earnings in each of the past 5 years.
EPIX had a negative operating cash flow in each of the past 5 years.
EPIX Yearly Net Income VS EBIT VS OCF VS FCFEPIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

EPIX's Return On Assets of -22.73% is fine compared to the rest of the industry. EPIX outperforms 74.58% of its industry peers.
EPIX has a Return On Equity of -23.07%. This is amongst the best in the industry. EPIX outperforms 82.43% of its industry peers.
Industry RankSector Rank
ROA -22.73%
ROE -23.07%
ROIC N/A
ROA(3y)-20.28%
ROA(5y)-21.7%
ROE(3y)-20.7%
ROE(5y)-22.14%
ROIC(3y)N/A
ROIC(5y)N/A
EPIX Yearly ROA, ROE, ROICEPIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K

1.3 Margins

EPIX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EPIX Yearly Profit, Operating, Gross MarginsEPIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, EPIX has less shares outstanding
EPIX has more shares outstanding than it did 5 years ago.
EPIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EPIX Yearly Shares OutstandingEPIX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
EPIX Yearly Total Debt VS Total AssetsEPIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

EPIX has an Altman-Z score of 0.99. This is a bad value and indicates that EPIX is not financially healthy and even has some risk of bankruptcy.
EPIX has a Altman-Z score of 0.99. This is in the better half of the industry: EPIX outperforms 61.50% of its industry peers.
There is no outstanding debt for EPIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.99
ROIC/WACCN/A
WACCN/A
EPIX Yearly LT Debt VS Equity VS FCFEPIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 69.06 indicates that EPIX has no problem at all paying its short term obligations.
The Current ratio of EPIX (69.06) is better than 99.63% of its industry peers.
EPIX has a Quick Ratio of 69.06. This indicates that EPIX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of EPIX (69.06) is better than 99.63% of its industry peers.
Industry RankSector Rank
Current Ratio 69.06
Quick Ratio 69.06
EPIX Yearly Current Assets VS Current LiabilitesEPIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

EPIX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.67%.
EPS 1Y (TTM)-6.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.72%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

EPIX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 72.82% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-13.16%
EPS Next 2Y30.89%
EPS Next 3Y6.83%
EPS Next 5Y72.82%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPIX Yearly Revenue VS EstimatesEPIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2029 2030 2031 2032 200M 400M 600M 800M
EPIX Yearly EPS VS EstimatesEPIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

EPIX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EPIX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EPIX Price Earnings VS Forward Price EarningsEPIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EPIX Per share dataEPIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.89%
EPS Next 3Y6.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EPIX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ESSA Pharma Inc

NASDAQ:EPIX (10/8/2025, 8:00:02 PM)

After market: 0.1951 -0.01 (-3.03%)

0.2012

0 (-1.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)12-15 2025-12-15/amc
Inst Owners73.7%
Inst Owner Change-3.66%
Ins Owners2.08%
Ins Owner Change-122630%
Market Cap9.52M
Revenue(TTM)N/A
Net Income(TTM)-25.12M
Analysts45.71
Price Target1.73 (759.84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date08-25 2025-08-25 (1.6910318)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.09
P/tB 0.09
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0
BVpS2.3
TBVpS2.3
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -22.73%
ROE -23.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.28%
ROA(5y)-21.7%
ROE(3y)-20.7%
ROE(5y)-22.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 69.06
Quick Ratio 69.06
Altman-Z 0.99
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.72%
EPS Next Y-13.16%
EPS Next 2Y30.89%
EPS Next 3Y6.83%
EPS Next 5Y72.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.01%
OCF growth 3YN/A
OCF growth 5YN/A

ESSA Pharma Inc / EPIX FAQ

What is the ChartMill fundamental rating of ESSA Pharma Inc (EPIX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to EPIX.


What is the valuation status of ESSA Pharma Inc (EPIX) stock?

ChartMill assigns a valuation rating of 0 / 10 to ESSA Pharma Inc (EPIX). This can be considered as Overvalued.


How profitable is ESSA Pharma Inc (EPIX) stock?

ESSA Pharma Inc (EPIX) has a profitability rating of 1 / 10.


Can you provide the financial health for EPIX stock?

The financial health rating of ESSA Pharma Inc (EPIX) is 8 / 10.